TY - JOUR
T1 - Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ
AU - Stackievicz, Rodica
AU - Paran, Haim
AU - Bernheim, Joelle
AU - Shapira, Mayra
AU - Weisenberg, Neomy
AU - Kaufman, Tzvi
AU - Klein, Ehud
AU - Gutman, Mordechai
PY - 2010/5
Y1 - 2010/5
N2 - Background: The prognostic significance of biologic markers in women with ductal carcinoma in situ is not fully understood. HER2/neu is a marker of prognostic significance that is routinely assessed in invasive cancer but its correlation with clinical outcome in DCIS is still obscure. Objectives: To evaluate the significance of HER-2/neu expression as a prognostic marker in DCIS. Methods: Clinical and pathologic data from 84 patients treated for DCIS were analyzed. HER-2/neu expression was determined by immunohistochemical staining. Histopathologic parameters (nuclear grade, histologic subtype, necrosis, calcifications, margins) were reviewed by an experienced pathologist. Local recurrence and/or metastatic spread were used as endpoints to determine the prognostic significance of HER-2/neu expression. Results: With a median follow-up of 94.8 months, nine recurrences were reported. Neither univariate nor multivariate analysis showed a significant correlation between HER-2/neu expression and disease recurrence or the time to disease recurrence. Although HER-2/neu expression demonstrated a significant association with high nuclear grade (P < 0.0001) and comedo subtype (P < 0.0001), there was no correlation between these histologic features and recurrence rate. The correlation between high nuclear grade and disease recurrence approached statistical significance (P= 0.07). Conclusions: No significant association was found between HER-2/neu expression in DCIS and disease recurrence. However, HER-2/neu correlated with negative markers such as nuclear grading and comedo necrosis, and its role should therefore be investigated in larger studies.
AB - Background: The prognostic significance of biologic markers in women with ductal carcinoma in situ is not fully understood. HER2/neu is a marker of prognostic significance that is routinely assessed in invasive cancer but its correlation with clinical outcome in DCIS is still obscure. Objectives: To evaluate the significance of HER-2/neu expression as a prognostic marker in DCIS. Methods: Clinical and pathologic data from 84 patients treated for DCIS were analyzed. HER-2/neu expression was determined by immunohistochemical staining. Histopathologic parameters (nuclear grade, histologic subtype, necrosis, calcifications, margins) were reviewed by an experienced pathologist. Local recurrence and/or metastatic spread were used as endpoints to determine the prognostic significance of HER-2/neu expression. Results: With a median follow-up of 94.8 months, nine recurrences were reported. Neither univariate nor multivariate analysis showed a significant correlation between HER-2/neu expression and disease recurrence or the time to disease recurrence. Although HER-2/neu expression demonstrated a significant association with high nuclear grade (P < 0.0001) and comedo subtype (P < 0.0001), there was no correlation between these histologic features and recurrence rate. The correlation between high nuclear grade and disease recurrence approached statistical significance (P= 0.07). Conclusions: No significant association was found between HER-2/neu expression in DCIS and disease recurrence. However, HER-2/neu correlated with negative markers such as nuclear grading and comedo necrosis, and its role should therefore be investigated in larger studies.
KW - Ductal carcinoma in situ
KW - Her-2/neu
KW - Markers
KW - Prognosis
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=77953503334&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 20929083
AN - SCOPUS:77953503334
SN - 1565-1088
VL - 12
SP - 290
EP - 295
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 5
ER -
